恆瑞醫藥(600276.SH):羥乙磺酸達爾西利片藥品上市許可申請獲受理
格隆匯5月8日丨恆瑞醫藥(600276.SH)公佈,收到國家藥品監督管理局下發的《受理通知書》,公司自主研發的CDK4/6抑制劑羥乙磺酸達爾西利片藥品上市許可申請獲國家藥監局受理。SHR6390-Ⅲ-303主要研究目的爲評價達爾西利聯合內分泌治療在HR陽性、HER2陰性乳腺癌輔助治療中的有效性,由復旦大學附屬腫瘤醫院及天津市腫瘤醫院牽頭的約150家中心完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.